Therefore, we investigated the mechanism by which FOS ameliorate steatohepatitis and tested our hypothesis that FOS alleviate visceral adiposity using an MSG-treated obese mouse model of NASH. Here, FOS is linked to metabolic dysfunction-associated steatohepatitis.